semaglutide india generic India's Dr Reddy's plans to launch obesity drugs in 87 countries next year, CEO says Sun Pharma, Dr. Reddy's, Zydus,

This inhibition consecutively leads to post-prandial GLP-1 plasma concentrations that are elevated 2-3-fold and mediates the glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion (Table 1 gives a summary of the clinical phase III studies with at least 52 weeks duration on the efficacy of DPP-4 inhibitors compared to sulfonylureas as add on therapy to metformin, respectively, in patients not reaching their glycaemic goals with a monotherapy of metformin

hence, their combination may synergize

Budhiraja P, Reddy KS, Butterfield RJ, Jadlowiec CC, Moss AA, Khamash HA, Kodali L, Misra SS, Heilman RL

Estimates from a meta-analysis suggest that the global prevalence of nonalcoholic fatty liver disease (NAFLD) is 30.1%, with a significant increase from 25.3% (19902006) to 38.2% (20162019) over the last three decades